The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system

Human Molecular Genetics

Volumn 18, Issue 16, 2009, Pages 2929-2942

  Chiang, Ming Chang ^a,b   Chen, Hui Mei ^a   Lai, Hsing Lin ^a   Chen, Hsiao Wen ^b   Chou, Szu Yi ^a   Chen, Chiung Mei ^c   Tsai, Fuu Jen ^d   Chern, Yijuang ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; AMMONIA; ARGINASE; ARGININOSUCCINATE LYASE; ARGININOSUCCINATE SYNTHASE; CITRULLINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; MUTANT PROTEIN; UBIQUITIN; UREA; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A2A RECEPTOR; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PROTEASOME; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, MOUSE;

AMMONIA BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME DEFICIENCY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UREA CYCLE; ANIMAL; CELL LINE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; LIVER; METABOLISM;

ADENOSINE; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; LIVER; MALE; MICE; PHENETHYLAMINES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, ADENOSINE A2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; UBIQUITIN; UREA;

EID: 68049096318     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp230     Document Type: Article

References (112)

1. Martin, J.B. and Gusella, J.F. (1986) Huntington's disease. Pathogenesis and management. N. Engl. J. Med., 315, 1267-1276.
2. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P. Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
3. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
4. Reddy, P.H., Williams, M. and Tagle, D.A. (1999) Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci., 22, 248.
5. Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H. and Wanker, E.E. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell, 12, 1393-1407.
6. Jana, N.R., Tanaka, M., Wang, G.-h. and Nukina, N. (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet., 9, 2009-2018.
7. Wyttenbach, A., Carmichael, J., Swartz, J., Furlong, R.A., Narain, Y., Rankin, J. and Rubinsztein, D.C. (2000) Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA, 97, 2898-2903.
8. Wyttenbach, A., Swartz, J., Kita, H., Thykjaer, T., Carmichael, J., Bradley, J., Brown, R., Maxwell, M., Schapira, A., Orntoft, T.F. et al. (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet., 10, 1829-1845.
9. Suhr, S.T., Senut, M.-C., Whitelegge, J.P., Faull, K.F., Cuizon, D.B. and Gage, F.H. (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J. Cell Biol., 153, 283-294.
10. Wanderer, J. and Morton, A.J. (2007) Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease. Histochem. Cell Biol., 127, 473-484.
11. Busch, A., Engemann, S., Lurz, R., Okazawa, H., Lehrach, H. and Wanker, E.E. (2003) Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: A potential mechanism for loss of huntingtin function in Huntington's disease. J. Biol. Chem., 278, 41452-41461.
12. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
13. Nucifora, F.C. Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
14. Kegel, K.B., Meloni, A.R., Yi, Y., Kim, Y.J., Doyle, E., Cuiffo, B.G., Sapp, E., Wang, Y., Qin, Z.H., Chen, J.D. et al. (2002) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem., 277, 7466-7476.
15. Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 296, 2238-2243.
16. Li, S.H., Cheng, A.L., Zhou, H., Lam, S., Rao, M., Li, H. and Li, X.J. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol., 22, 1277-1287.
17. 2A adenosine receptor promoter by mutant huntingtin with expanded polyglutamine residues. J. Biol. Chem., 280, 14331-14340.
18. Chiang, M.-C., Juo, C.-G., Chang, H.-H., Chen, H.-M., Yi, E.C. and Chern, Y. (2007) Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach. Mol. Cell. Proteomics, 6, 781-797.
19. Ravikumar, B., Stewart, A., Kita, H., Kato, K., Duden, R. and Rubinsztein, D.C. (2003) Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum. Mol. Genet., 12, 985-994.
20. Ferrante, R.J., Kubilus, J.K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N.W., Ratan, R.R., Luthi-Carter, R. et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci., 23, 9418-9427.
21. Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J.M. and Cattaneo, E. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet., 11, 1953-1965.
22. Chan, E.Y., Luthi-Carter, R., Strand, A., Solano, S.M., Hanson, S.A., DeJohn, M.M., Kooperberg, C., Chase, K.O., DiFiglia, M., Young, A.B. et al. (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet., 11, 1939-1951.
23. Luthi-Carter, R., Strand, A.D., Hanson, S.A., Kooperberg, C., Schilling, G., La Spada, A.R., Merry, D.E., Young, A.B., Ross, C.A., Borchelt, D.R. et al. (2002) Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet., 11, 1927-1937.
24. Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B.R., Hayden, M.R., Timmusk, T. et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet., 35, 76.
25. Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I. and Myers, R.H. (2002) Weight loss in early stage of Huntington's disease. Neurology, 59, 1325-1330.
26. Ribchester, R.R., Thomson, D., Wood, N.I., Hinks, T., Gillingwater, T.H., Wishart, T.M., Court, F.A. and Morton, A.J. (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci., 20, 3092-3114.
27. Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E.E., Doherty, P., Davies, S.W. and Bates, G.P. (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet., 8, 813-822.
28. Phan, J., Hickey, M.A., Zhang, P., Chesselet, M.-F. and Reue, K. (2009) Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet., 18, 1006-1016.
29. Mihm, M.J., Amann, D.M., Schanbacher, B.L., Altschuld, R.A., Bauer, J.A. and Hoyt, K.R. (2007) Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 25, 297-308.
30. Bjorkqvist, M., Wild, E.J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R.V., Benn, C.L., Soulet, D. et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med., 205, 1869-1877.
31. Valenza, M., Carroll, J.B., Leoni, V., Bertram, L.N., Bjorkhem, I., Singaraja, R.R., Di Donato, S., Lutjohann, D., Hayden, M.R. and Cattaneo, E. (2007) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum. Mol. Genet. 16, 2187-2198.
32. Chiang, M.-C., Chen, H.-M., Lee, Y.-H., Chang, H.-H., Wu, Y.-C., Soong, B.-W., Chen, C.-M., Wu, Y.-R., Liu, C.-S., Niu, D.-M. et al. (2007) Dysregulation of C/EBPfalphag by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease. Hum. Mol. Genet., 16, 483-498.
33. Martin, B., Golden, E., Keselman, A., Stone, M., Mattson, M.P., Egan, J.M. and Maudsley, S. (2008) Therapeutic perspectives for the treatment of Huntington's disease: Treating the whole body. Histol. Histopathol., 23, 237-250.
34. DeMartino, G.N. and Gillette, T.G. (2007) Proteasomes: Machines for all reasons. Cell, 129, 659-662.
35. Hershko, A. and Ciechanover, A. (1998) The ubiquitin system. Ann. Rev. Biochem., 67, 425-479.
36. von Mikecz, A. (2006) The nuclear ubiquitin-proteasome system. J. Cell Sci., 119, 1977-1984.
37. McBride, W.H., Iwamoto, K.S., Syljuasen, R., Pervan, M. and Pajonk, F. The role of the ubiquitin//proteasome system in cellular responses to radiation. Oncogene, 22, 5755-5773.
38. Muratani, M. and Tansey, W.P. (2003) How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell. Biol., 4, 192-201.
39. Hegde, A.N. and Upadhya, S.C. (2007) The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci., 30 587-595.
40. Ding, Q., Cecarini, V. and Keller, J.N. (2007) Interplay between protein synthesis and degradation in the CNS: Physiological and pathological implications. Trends Neurosci., 30, 31-36.
41. Nandi, D., Tahiliani, P., Kumar, A. and Chandu, D. (2006) The ubiquitin-proteasome system. J. Biosci., 31, 137-155.
42. McBride, W.H., Iwamoto, K.S., Syljuasen, R., Pervan, M. and Pajonk, F. (2003) The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene, 22, 5755-5773.
43. Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-1555.
44. Ross, C.A. and Pickart, C.M. (2004) The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol., 14, 703-711.
45. van Tijn, P., Hol, E.M., van Leeuwen, F.W. and Fischer, D.F. (2008) The neuronal ubiquitin-proteasome system: Murine models and their neurological phenotype. Prog. Neurobiol., 85, 176-193.
46. Bennett, E.J., Shaler, T.A., Woodman, B., Ryu, K.-Y., Zaitseva, T.S., Becker, C.H., Bates, G.P., Schulman, H. and Kopito, R.R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature, 448, 704-708.
47. Wang, J., Wang, C.-E., Orr, A., Tydlacka, S., Li, S.-H. and Li, J. (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol., 180, 1177-1189.
48. Seo, H., Sonntag, K.C. and Isacson, O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol., 56 319-328.
49. Doi, H., Mitsui, K., Kurosawa, M., Machida, Y., Kuroiwa, Y. and Nukina, N. (2004) Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett., 571, 171-176.
50. Zhou, H., Cao, F., Wang, Z., Yu, Z.-X., Nguyen, H.-P., Evans, J., Li, S.-H. and Li, J. (2003) Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J. Cell Biol., 163, 109-118.
51. Hunter, J.M., Lesort, M. and Johnson, G.V.W. (2007) Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res., 85, 1774-1788.
52. Seo, H., Kim, W. and Isacson, O. (2008) Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum. Mol. Genet., 17, 3144-3153.
53. Wang, J., Wang, C.E., Orr, A., Tydlacka, S., Li, S.H. and Li, X.J. (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol., 180, 1177-1189.
54. Valera, A.G., Diaz-Hernandez, M., Hernandez, F. and Lucas, J.J. (2007) Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. Brain Res. Bull., 72 121-123.
55. Chern, Y., King, K., Lai, H.L. and Lai, H.T. (1992) Molecular cloning of a novel adenosine receptor gene from rat brain. Biochem. Biophy. Res. Commun., 185, 304-309.
56. Lee, Y.-C., Chien, C.-L., Sun, C.-N., Huang, C.-L., Huang, N.-K., Chiang, M.-C., Lai, H.-L., Lin, Y.-S., Chou, S.-Y., Wang, C.-K.L. et al. (2003) Characterization of the rat A2A adenosine receptor gene: A 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. Eur. J. Neurosci., 18, 1786-1796.
57. Chern, Y., Lai, H.L., Fong, J.C. and Liang, Y. (1993) Multiple mechanisms for desensitization of A2a adenosine receptor-mediated cAMP elevation in rat pheochromocytoma PC12 cells. Mol. Pharmacol., 44, 950-958.
58. Huang, N.-K., Lin, Y.-W., Huang, C.-L., Messing, R.O. and Chern, Y. (2001) Activation of protein kinase A and atypical protein kinase C by A2A adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. J. Biol. Chem., 276, 13838-13846.
59. Walker, B.A., Rocchini, C., Boone, R.H., Ip, S. and Jacobson, M.A. (1997) Adenosine A2a receptor activation delays apoptosis in human neutrophils. J. Immunol., 158, 2926-2931.
60. Day, Y.J., Huang, L., McDuffie, M.J., Rosin, D.L., Ye, H., Chen, J.F., Schwarzschild, M.A., Fink, J.S., Linden, J. and Okusa, M.D. (2003) Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest., 112, 883-891.
61. Day, Y.J., Marshall, M.A., Huang, L., McDuffie, M.J., Okusa, M.D. and Linden, J. (2004) Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: Inhibition of chemokine induction. Am. J. Physiol. Gastrointest. Liver Physiol., 286 G285-G293.
62. Ferre, S., O'Connor, W.T., Fuxe, K. and Ungerstedt, U. (1993) The striopallidal neuron: A main locus for adenosine - dopamine interactions in the brain. J. Neurosci., 13, 5402-5406.
63. Weaver, D.R. (1993) A2a adenosine receptor gene expression in developing rat brain. Brain Res. Mol. Brain Res., 20, 313-327.
64. Glass, M., Dragunow, M. and Faull, R.L. (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97 505-519.
65. Popoli, P., Pezzola, A., Reggio, R., Caporali, M.G. and Scotti de Carolis, A. (1994) CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. Eur. J. Pharmacol., 257, R5-R6.
66. Popoli, P., Pintor, A., Domenici, M.R., Frank, C., Tebano, M.T., Pezzola, A., Scarchilli, L., Quarta, D., Reggio, R., Malchiodi-Albedi, F. et al. (2002) Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci., 22 1967-1975.
67. Blum, D., Galas, M.C., Pintor, A., Brouillet, E., Ledent, C., Muller, C.E., Bantubungi, K., Galluzzo, M., Gall, D., Cuvelier, L. et al. (2003) A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A2A antagonists. J. Neurosci., 23, 5361-5369.
68. Fink, J.S., Kalda, A., Ryu, H., Stack, E.C., Schwarzschild, M.A., Chen, J.F. and Ferrante, R.J. (2004) Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem., 88, 538-544.
69. Popoli, P., Blum, D., Domenici, M.R., Burnouf, S. and Chern, Y. (2008) A critical evaluation of adenosine A2A receptors as potentially 'druggable' targets in Huntington's disease. Curr. Pharm. Design, 14, 1500-1511.
70. Chou, S.Y., Lee, Y.C., Chen, H.M., Chiang, M.C., Lai, H.L., Chang, H.H., Wu, Y.C., Sun, C.N., Chien, C.L., Lin, Y.S. et al. (2005) CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem., 93, 310-320.
71. Martire, A., Calamandrei, G., Felici, F., Scattoni, M.L., Lastoria, G., Domenici, M.R., Tebano, M.T. and Popoli, P. (2007) Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci. Lett., 417, 78-83.
72. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
73. Tarditi, A., Camurri, A., Varani, K., Borea, P.A., Woodman, B., Bates, G., Cattaneo, E. and Abbracchio, M.P. (2006) Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis., 23, 44-53.
74. Glass, M., Dragunow, M. and Faull, R.L.M. (2000) The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97 505-519.
75. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9 1259-1271.
76. Fujimoto, M., Takaki, E., Hayashi, T., Kitaura, Y., Tanaka, Y., Inouye, S. and Nakai, A. (2005) Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem., 280, 34908-34916.
77. Mitra, S., Tsvetkov, A.S. and Finkbeiner, S. (2009) Single-neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in Huntington's disease. J. Biol. Chem., 284, 4398-4403.
78. Tydlacka, S., Wang, C.E., Wang, X., Li, S. and Li, X.J. (2008) Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J. Neurosci., 28, 13285-13295.
79. Bennett, E.J., Shaler, T.A., Woodman, B., Ryu, K.Y., Zaitseva, T.S., Becker, C.H., Bates, G.P., Schulman, H. and Kopito, R.R. (2007) Global changes to the ubiquitin system in Huntington's disease. Nature, 448, 704-708.
80. Ortega, Z., Diaz-Hernandez, M. and Lucas, J.J. (2007) Is the ubiquitin-proteasome system impaired in Huntington's disease? Cell. Mol. Life Sci., 64, 2245-2257.
81. Hunter, J.M., Lesort, M. and Johnson, G.V. (2007) Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res., 85, 1774-1788.
82. Bett, J.S., Goellner, G.M., Woodman, B., Pratt, G., Rechsteiner, M. and Bates, G.P. (2006) Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: Exclusion of proteasome activator REGgamma as a therapeutic target. Hum. Mol. Genet., 15, 33-44.
83. Seki, T., Takahashi, H., Adachi, N., Abe, N., Shimahara, T., Saito, N. and Sakai, N. (2007) Aggregate formation of mutant protein kinase C gamma found in spinocerebellar ataxia type 14 impairs ubiquitin-proteasome system and induces endoplasmic reticulum stress. Eur. J. Neurosci., 26, 3126-3140.
84. Flajolet, M., Wang, Z., Futter, M., Shen, W., Nuangchamnong, N., Bendor, J., Wallach, I., Nairn, A.C., Surmeier, D.J. and Greengard, P. (2008) FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci., 11, 1402-1409.
85. Lee, F.S. and Chao, M.V. (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl Acad. Sci. USA, 98 3555-3560.
86. Wiese, S., Jablonka, S., Holtmann, B., Orel, N., Rajagopal, R., Chao, M.V. and Sendtner, M. (2007) Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc. Natl Acad. Sci. USA, 104, 17210-17215.
87. Domenici, M.R., Scattoni, M.L., Martire, A., Lastoria, G., Potenza, R.L., Borioni, A., Venerosi, A., Calamandrei, G. and Popoli, P. (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis., 28, 197-205.
88. Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N.R., Doi, H., Kurosawa, M., Nekooki, M. and Nukina, N. (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med., 10, 148-154.
89. Lu, H., Zong, C., Wang, Y., Young, G.W., Deng, N., Souda, P., Li, X., Whitelegge, J., Drews, O., Yang, P.Y. et al. (2008) Revealing the dynamics of 20S proteasome phosphoproteome: A combined CID and ETD approach. Mol. Cell. Proteomics, 7, 2073-2089.
90. Zhang, F., Hu, Y., Huang, P., Toleman, C.A., Paterson, A.J. and Kudlow, J.E. (2007) Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J. Biol. Chem., 282, 22460-22471.
91. Andreassen, O.A., Dedeoglu, A., Stanojevic, V., Hughes, D.B., Browne, S.E., Leech, C.A., Ferrante, R.J., Habener, J.F., Beal, M.F. and Thomas, M.K. (2002) Huntington's disease of the endocrine pancreas: Insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis., 11, 410-424.
92. Mingote, S., Pereira, M., Farrar, A.M., McLaughlin, P.J. and Salamone, J.D. (2008) Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacol. Biochem. Behav., 89, 345-351.
93. Gordi, T., Frohna, P., Sun, H.L., Wolff, A., Belardinelli, L. and Lieu, H. (2006) A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin. Pharmacokinetics, 45, 1201-1212.
94. Gao, Z.G. and Jacobson, K.A. (2004) Partial agonists for A(3) adenosine receptors. Curr. Top. Med. Chem., 4, 855-862.
95. Hay, D.G., Sathasivam, K., Tobaben, S., Stahl, B., Marber, M., Mestril, R., Mahal, A., Smith, D.L., Woodman, B. and Bates, G.P. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet., 13, 1389-1405.
96. Kobayashi, Y., Kume, A., Li, M., Doyu, M., Hata, M., Ohtsuka, K. and Sobue, G. (2000) Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275, 8772-8778.
97. Muchowski, P.J., Schaffar, G., Sittler, A., Wanker, E.E., Hayer-Hartl, M.K. and Hartl, F.U. (2000) Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl Acad. Sci. USA, 97, 7841-7846.
98. Perrin, V., Regulier, E., Abbas-Terki, T., Hassig, R., Brouillet, E., Aebischer, P., Luthi-Carter, R. and Deglon, N. (2007) Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol. Ther., 15, 903-911.
99. Wyttenbach, A., Sauvageot, O., Carmichael, J., Diaz-Latoud, C., Arrigo, A.P. and Rubinsztein, D.C. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet., 11, 1137-1151.
100. Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M.K., Hartl, F.U. and Wanker, E.E. (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet., 10, 1307-1315.
101. Zou, J., Guo, Y., Guettouche, T., Smith, D.F. and Voellmy, R. (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94, 471-480.
102. Calabrese, V., Renis, M., Calderone, A., Russo, A., Barcellona, M.L. and Rizza, V. (1996) Stress proteins and SH-groups in oxidant-induced cell damage after acute ethanol administration in rat. Free Rad. Biol. Med., 20, 391-397.
103. Calabrese, V., Renis, M., Calderone, A., Russo, A., Reale, S., Barcellona, M.L. and Rizza, V. (1998) Stress proteins and SH-groups in oxidant-induced cellular injury after chronic ethanol administration in rat. Free Rad. Biol. Med., 24, 1159-1167.
104. Conconi, M., Petropoulos, I., Emod, I., Turlin, E., Biville, F. and Friguet, B. (1998) Protection from oxidative inactivation of the 20S proteasome by heat-shock protein 90. Biochem. J., 333, 407-415.
105. Bedford, L., Hay, D., Devoy, A., Paine, S., Powe, D.G., Seth, R., Gray, T., Topham, I., Fone, K., Rezvani, N. et al. (2008) Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci., 28, 8189-8198.
106. Liao, C.W., Fan, C.K., Kao, T.C., Ji, D.D., Su, K.E., Lin, Y.H. and Cho, W.L. (2008) Brain injury-associated biomarkers of TGF-beta1, S100B, GFAP, NF-L, tTG, AbetaPP, and tau were concomitantly enhanced and the UPS was impaired during acute brain injury caused by Toxocara canis in mice. BMC Infect. Dis., 8, 84.
107. Seo, H., Sonntag, K.C. and Isacson, O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol., 56 319-328.
108. Diaz-Hernandez, M., Hernandez, F., Martin-Aparicio, E., Gomez-Ramos, P., Moran, M.A., Castano, J.G., Ferrer, I., Avila, J. and Lucas, J.J. (2003) Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci., 23, 11653-11661.
109. Dahlmann, B. (2007) Role of proteasomes in disease. BMC Biochem., 8 (Suppl. 1), S3.
110. Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
111. Liu, F.-C., Wu, G.-C., Hsieh, S.-T., Lai, H.-L., Wang, H.-F., Wang, T.-W. and Chern, Y. (1998) Expression of type VI adenylyl cyclase in the central nervous system: Implication for a potential regulator of multiple signals in different neurotransmitter systems. FEBS Lett. 436, 92.
112. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.